

ERRATUM

Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT

Andrew Hughes · Donal Landers · Hendrik-Tobias Arkenau · Saj Shah ·
Richard Stephens · Amrik Mahal · Matthew Simmons · Charlotte Lemech ·
Jennifer Royle

Published online: July 27, 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Erratum to: Adv Ther (2016) 33:1012–1024
DOI 10.1007/s12325-016-0335-4

Following publication of the aforementioned article the authors noticed that a sentence had been omitted from the acknowledgements section pertaining to the AstraZeneca development team. The acknowledgements section should read as follows:

The online version of the original article can be found under doi:[10.1007/s12325-016-0335-4](https://doi.org/10.1007/s12325-016-0335-4).

A. Hughes
Manchester Cancer Research Centre, University of
Manchester, Manchester, UK

D. Landers · S. Shah · A. Mahal · J. Royle
AstraZeneca, Cambridge, UK

H.-T. Arkenau · M. Simmons · C. Lemech
Sarah Cannon Research Institute, London, UK

H.-T. Arkenau · C. Lemech
University College London, London, UK

R. Stephens
Consumer Forum, National Cancer Research
Institute, London, UK

Present Address:
J. Royle (✉)
Cancer Research UK Manchester Institute,
The University of Manchester, Manchester, UK
e-mail: Jenny.Royle@cruk.manchester.ac.uk

ACKNOWLEDGMENTS

We thank all the patients who took part in the study, colleagues within the Sarah Cannon Research Institute UK site who cared for these patients, and Bartley O'Connor of Sqeeler Limited for the IT platform used during this pilot study. We also thank David Peters of Sequoia Medical Communications Ltd, who provided medical writing assistance funded by AstraZeneca, and colleagues within the AstraZeneca development team (most notably Åsa Strom, Stephanie Roberts, Christelle Gendrin, Paul Bonnet, Shamma Iqbal, and Shirley Spratt). This study was sponsored by AstraZeneca. The article processing charges and open access fee for this publication were funded by AstraZeneca. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License

(<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the

original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.